Abstract: Erlotinib is metabolized by cytochrome p450 (CYP) 3A and CYP1A. This study assessed CYP3A4 (midazolam) and CYP1A2 (caffeine) phenotyping in plasma and dried blood spots (DBS) for predicting the pharmacokinetics and toxicity of erlotinib in 36 patients with advanced NSCLC. On day 1, erlotinib 150 mg OD was initiated, and the two oral probe drugs midazolam (2 mg) and caffeine (100 mg) were added on day 1. Plasma and DBS were collected for erlotinib, OSI-420 and probe drugs for up to 6 hr on day 1 and 2-weekly up to week 10. Probe drugs, erlotinib and OSI-420 were analysed using LC-MS-MS, and PK data were processed using population modelling. A high correlation was found between plasma and DBS concentrations for erlotinib (R 2 = 0.960, p < 0.0001), OSI-420 (R 2 = 0.971, p < 0.0001), midazolam (R 2 = 0.995, p < 0.0001) and caffeine (R 2 = 0.968, p < 0.0001). Apparent oral caffeine clearance was significantly correlated with erlotinib clearance (R 2 = 0.33, p = 0.048), while midazolam clearance was not (R 2 = À0.09, p = 0.596). Erlotinib clearance was lower in patients experiencing grade 2 or 3 rash as compared to patients experiencing grade 0 or 1 rash (3.15 versus 3.93 L/hr, p = 0.086 for Student's t-test). The results suggest that probe drug phenotyping is unlikely to substitute therapeutic drug monitoring of erlotinib in patients with advanced NSCLC, but erlotinib PK sampling from DBS may replace more invasive venous sampling and facilitate TDM in patients with cancer.
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Erlotinib is a first-generation oral epidermal growth factor receptor (EGFR) inhibitor that is approved in patients with advanced EGFR wild-type non-small-cell lung cancer (NSCLC) in second-or third-line treatment after platinumbased chemotherapy [1] and in patients with EGFR-mutant advanced NSCLC in first-line treatment [2, 3] . After the discovery of the epidermal growth factor receptor (EGFR) mutation and its association with tumour response [4, 5] , tumour EGFR mutation analysis has helped to guide the use of erlotinib and other EGFR small-molecule inhibitors in advanced NSCLC [2] . Erlotinib exhibits linear pharmacokinetics (PK), with an average elimination half-life of 24 hr, and substantial interindividual variability [6] . Erlotinib is metabolized by intestinal CYP3A4 and hepatic CYP3A4 and CYP1A2 [7] , making the drug prone to interactions with other drugs and smoking [8] . Sources of pharmacological variability, potentially resulting in under-or overexposure, include comedication with proton pump inhibitors (PPI) and reduced gastrointestinal absorption [9] , the influence of acidic beverages such as cola [10] and the dependence of drug absorption on the feeding state of the patient [11] . In addition, PK variability and in particular underexposure may result in non-efficacy and/or more rapid development of acquired resistance to erlotinib in EGFR-mutant lung cancer [12] . For these reasons, erlotinib has been suggested as a potential candidate for therapeutic drug monitoring (TDM) or other pharmacological tools for dosing optimization [13] .
Human cytochrome P450 enzymes (CYPs) are responsible for oxidative metabolism of approximately 50% of commonly prescribed drugs and the majority of oral small-molecule anticancer drugs such as the tyrosine kinase inhibitors. Individual enzymatic CYP activity is an important source of interindividual PK variability [14] . While germline pharmacogenetic factors can be assessed by genotyping, the interacting effects of, for example comedication, organ dysfunction or lifestyle factors such as smoking on CYP enzymes can only be assessed by phenotyping [15] . Accordingly, phenotyping for drug metabolizing enzymes is used to assess quantitatively the overall effect of an intervention such as concomitant drug treatment as well as other conditions such as genetic polymorphism on their activity [15] . Oral caffeine and midazolam are the recommended and most frequently used probe drugs for CYP1A2 and CYP3A4, respectively [15] . Phenotyping procedures may be combined to simultaneously assess multiple metabolic profiles, such as has been performed with the 'Basel' probe drug 'cocktail' by our group [16, 17] . This has been shown to be safe without severe adverse events or mutual drug interactions. This study was initiated to evaluate whether CYP3A4 and 1A2 phenotyping may be used to inform individualized erlotinib dosing in patients with advanced NSCLC, and whether dried blood spot (DBS) analysis of erlotinib may facilitate TDM of erlotinib.
Materials and Methods
Patients and study treatment. This prospective, non-randomized, pharmacological study (NCT01402089) was carried out at the Cantonal Hospital St. Gallen (Switzerland). It was approved by the Ethics Committee of Eastern Switzerland (SG 327/10) and Swissmedic (2011DR1163). All procedures performed in this trial were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its amendments. Pre-treatment evaluation included a medical and physical examination, baseline radiological tumour measurement and blood sampling. Main eligibility criteria included patients with cytologically or histologically confirmed advanced, inoperable NSCLC who started treatment with oral erlotinib 150 mg OD in fasting conditions. Patients had either EGFR wild-type or EGFR-mutant NSCLC and received erlotinib within its approved label. Treatment was continued until disease progression, intolerable toxicity or withdrawal of patient consent, whatever occurred first. Basic haematology assessments were performed at weekly intervals. Major comedication was collected for all patients during erlotinib treatment. Radiological assessments of tumour response were repeated every 8 weeks. Patients had to have adequate bone marrow function (absolute neutrophil count (ANC) ≥1.5 G/L, platelet count ≥100 G/L), an ECOG performance score of ≤2, willingness to undergo repeated pharmacokinetic (PK) sampling, age 18 years or older and a life expectancy of >12 weeks. Informed consent was obtained from all individual participants included in the study. On day 1 and after an overnight fast, oral erlotinib was started at 150 mg OD and administered concurrently with a single administration of oral midazolam 2 mg and oral caffeine 100 mg (Mylan Dura GmbH, Darmstadt, Germany) after a 48-hr caffeine abstinence. Daily erlotinib was taken at fasting conditions, and drug compliance was assessed using a conventional patient diary. Patients were allowed to receive potentially interacting drugs such as PPI or minocycline to image real-life clinical conditions. Pharmacokinetic blood sampling and bioanalysis. Blood was sampled for both probe drugs, erlotinib and its metabolite OSI-420 at baseline (pre-treatment), 1, 2, 3, 4 and 6 hr after drug administration on day 1 and for erlotinib and OSI-420 at steady-state at 2, 4, 8 and 10 weeks (trough levels) after the start of erlotinib treatment. Capillary blood sampling was carried out at 2, 4, 6 hr after drug intake, followed by 2, 4, 8 and 10 weeks. Blood was immediately put on ice after sampling and processed into plasma that was stored at À80°C until analysis. Probe drugs, erlotinib and metabolites were analysed using LC-MS/MS In brief, 50 lL aliquots of plasma was mixed with 150 lL of internal standard solution (100 ng/mL erlotinib-d6 in methanol) and then centrifuged at 3200 9 g for 30 min. at 10°C. For DBS analysis, a disc with a diameter of 3 mm was cut out of the centre of the DBS and added to a vial containing 200 lL of the internal standard solution (100 ng/mL erlotinib-d6 in methanol/water (1/1, v/v). The vials were then vortexmixed for 10 min. and centrifuged (3200 9 g; 30 min.; 10°C). To perform the analysis, an aliquot of the supernatant was injected into the LC-MS/MS system consisting of a quaternary Shimadzu HPLC system (Kyoto, Japan) coupled to an API 3200 or API 4000 tandem mass spectrometer ( AB Sciex, Ontario, Canada). The analytes were analysed using electrospray ionization with multiple reaction monitoring in positive polarity mode. The following mass transitions were used as follows: erlotinib; m/z 394?278, OSI-420; m/z 380 ?278/276 and erlotinib-d6; m/z 400?278. Analyst software version 1.6.2 (AB Sciex) was used to operate the LC-MS/MS system. A representative chromatogram showing the retention time and separation of the analytes is shown in Figure S1 . The total run time was 3.0 min. Linearity was attained over a calibration range of 10 to 10,000 ng/ml for erlotinib and 2.5-2500 ng/mL for OSI-420. For all qualification runs, the coefficient of determination (R 2 ) was >0.99 for erlotinib as well as OSI-420. The signal in a blank sample after injection of the highest calibrator was ten times lower than the signal detected at LLOQ, indicating negligible analyte carry-over. Noise level baselines of blank plasma and DBS did not show co-eluting peaks at the retention time of erlotinib and OSI-420 ( Figure S1 ). The calculated intraday accuracy was between 99.5-108.3% for DBS samples and between 89.4-105.7% for plasma samples (Tables S1 and S2) . Capillary blood sampling (DBS) was carried out on a blood collection card (filter paper) using a standard finger prick procedure. At least two (and up to a maximum of five) pre-printed circles were uniformly saturated with patient blood, and capillary blood specimens were allowed to fully air-dry at room temperature (light protected). Filter papers were inserted into sealable plastic bags for transport and before subsequent bioanalysis using UPLC-MS-MS.
Pharmacokinetic data were processed using population modelling (NONMEM v.7.3). Basic and covariate PK models were explored for erlotinib, midazolam and caffeine. Model selection was based on objective function values, goodness-of-fit plots and precision in parameter estimates obtained by bootstrap in PsN (see also Supporting Information, Figure S2 , Table S3 ). The likelihood ratio test (LRT) was used to compare nested models, for which a reduction in the OFV of 3.84 points was considered statistically significant assuming a v 2 distribution (p-value: 0.01, degrees of freedom: 1). The Akaike information criterion (AIC) was used for non-nested models. Selected models were evaluated using visual predictive checks (VPC) in PsN. The quantitative impact of covariates including patient age, gender, comedication and smoking status was tested on drug clearance.
Statistical analysis. The primary study objective was to assess the association between the PK of the two probe drugs (midazolam, caffeine) and their major metabolites (OH-midazolam, paraxanthine) with erlotinib and its main metabolite OSI-420 using Pearson's correlation analysis. With the inclusion of 35 patients, the study has a power of 80% to detect a significant relationship between the apparent oral clearance (further referred to as 'clearance') of the two probe drugs and the clearance of erlotinib with a regression coefficient of ≥ À0.4 for the H1 hypothesis, supposing a regression coefficient of ≤ À0.1 for the H0 hypothesis. As a secondary objective, we assessed the correlation between plasma concentrations of erlotinib, the two probe drugs and all metabolites with the respective concentrations as measured in capillary blood using DBS. In addition, erlotinib-related categorical toxicity was compared with the clearance and the 3-hr parent-metabolite ratios of erlotinib and the two probe drugs using the Kruskal-Wallis test, analysis of variance and logistic regression analysis. Correlation analysis was performed between the smoking status and drug clearance. Progression-free survival (PFS) and overall survival (OS) were calculated using the method of Kaplan-Meier, and the prognostic impact of erlotinib clearance on PFS and OS was calculated using multivariate logistic regression analysis to correct for known prognostic covariates, including EGFR mutation status. Statistical tests were performed two-sided; p < 0.05 was considered significant. The statistical analyses were performed using the STATA 11.0 software (STATA Corp, College Station, TX, USA).
Results

Patients and study treatment.
A total of 37 patients were included into the study between January 2012 and May 2015. One patient was registered but did not receive treatment due to rapid deterioration of her health status. All 36 treated patients were evaluable for erlotinib-related toxicity, clinical outcome and pharmacokinetics of erlotinib and both probe drugs (midazolam, caffeine). Patient characteristics are outlined in Table 1 . Three patients harboured activating EGFR mutations and received erlotinib either as first-line (N = 2) or second-line palliative treatment (N = 1). The remaining 33 patients with EGFR wild-type, advanced NSCLC received erlotinib either in second-line (N = 24) or third-line treatment (N = 9). At the time of data analysis (May 2016), all except one patient with EGFR mutant NSCLC had discontinued erlotinib treatment due to disease progression. Four patients are still alive, including one patient with EGFR mutant NSCLC who is alive 18 months after initiating first-line erlotinib treatment. Two patients with EGRF mutant NSCLC experienced a radiological partial remission; no partial remission was seen in patients with EGFR wild-type NSCLC. Patients with EGFR wild-type NSCLC received erlotinib for a median of 8 weeks and experienced a median survival of 7.9 months. Nine of the 36 patients required at least one dose reduction of erlotinib (to a daily dose of 100 mg), with one patient with EGFR-mutant NSCLC receiving two dose reductions (to a daily dose of 75 mg) for skin rash and diarrhoea. A total of six patients received prophylactic minocycline for erlotinib-related skin rash.
Pharmacokinetics of erlotinib, midazolam and caffeine. Baseline PK samples taken before the start of erlotinib and probe drugs confirmed plasma concentrations for erlotinib, caffeine, midazolam and their metabolites below the lower limit of quantification (LLQ). The correlation between erlotinib concentrations measured in plasma versus those measured in parallel in capillary blood (DBS) is outlined in a Bland-Altman plot ( fig. 1) . The median bias between erlotinib plasma concentrations versus DBS was 102.0 ng/mL, meaning that erlotinib DBS concentrations are an average of 102 ng/mL (S.D. 370.3 ng/mL) higher than erlotinib plasma concentrations. The PK of erlotinib, OSI-420 and caffeine were adequately described using population PK modelling as described above (see also Supporting Information, Figure S2 , Table S3 ). Midazolam PK was best described using a two-compartment disposition model, while caffeine and erlotinib were described using a single-compartment population PK model [18] . Due to the fast drug absorption of midazolam and erlotinib, this process could not be identified based on the available PK data which is why the absorption rate constants were fixed to data as described in the literature (absorption rate constant of 3.18 hr À1 for midazolam [19] , 1.09 hr À1 for erlotinib [13] , respectively). Midazolam and erlotinib clearance were estimated to be solely dependent on metabolite formation. Finally, paraxanthine pharmacokinetics could not be characterized due to the short collection sampling time that covered only the formation but not the elimination phase. Detailed results of the population PK and pharmacodynamic analysis have been reported as abstract [18] and will be separately published as a full manuscript. Individual caffeine clearance was well fig. 4A,C) . Considering patients receiving prophylactic minocycline and not experiencing erlotinib-related skin rash CTC grade >2 as (potentially) experiencing skin rash CTC grade >2, these patients still had a lower erlotinib clearance that reached borderline statistical significance (3.27 versus 3.96 L/hr, p = 0.058). The mean 3-hr erlotinib/OSI-420 metabolic ratio was 10.7 (AE3.7), and it was not correlated with erlotinib-related toxicity including rash. Caffeine clearance was numerically lower in patients with grade 2 or 3 rash as compared to patients with grade 0 or 1 rash (3.19 versus 4.02 L/hr, p = 0.090 for Student's t-test). The mean 3-hr midazolam/OH-midazolam metabolic ratio was 4.8 (AE1.7), and it was not correlated with erlotinib-related toxicity including rash. Comedication as outlined in Table 1 had no significant impact on the clearance of erlotinib, midazolam or caffeine. Erlotinib clearance was no prognostic factor for PFS (p = 0.076) or OS (p = 0.270) in the multivariate model, adjusting for patient age, gender, performance status, the presence of activating EGFR mutations in three patients, tumour stage (inoperable stage III, stage IV) and smoking status. ECOG performance status (HR = 3.78, p < 0.0001) and smoking status (HR = 3.01, p = 0.020) were the only significant and independent prognostic factors for OS in the adjusted model.
Discussion
This is the first clinical study assessing the performance of a probe drug approach for CYP3A4 (midazolam) and CYP1A2
(caffeine) in patients with advanced NSCLC receiving the oral EGFR-targeting tyrosine kinase inhibitor erlotinib. Our group has previously shown the feasibility and validity of simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and DBS [16, 17] . This 'Basel cocktail' used simultaneous phenotyping of CYP1A2, 2B6, 2C9, 2C19, 2D6 and 3A4 with giving low doses of the respective probe drugs, including oral caffeine at 100 mg and 2 mg midazolam as an oral solution [16, 17] , which was the basis of the phenotyping approach as used in the present study. While erlotinib is a known substrate of both CYP3A and CYP1A isoforms, the latter subfamily is considerably involved in erlotinib metabolism [20] . Interestingly, the individual PK of midazolam, which reflects CYP3A4 activity, was not found to be associated with erlotinib PK and/or toxicity in this study. Midazolam is therefore not suggested as a suitable probe drug for predicting erlotinib PK and/or toxicity in this group of patients. There are several potential reasons as to why we did not find an association between CYP3A4 activity as assessed by midazolam elimination and the elimination of erlotinib. As the majority of patients were current smokers or stopped smoking shortly before starting erlotinib treatment, there was likely a substantial induction of CYP1A with a potential larger impact of the latter on erlotinib metabolism. Additionally, factors such as comedication, comorbidity or subclinical liver dysfunction may have added to the substantial interindividual variability of erlotinib elimination and have blunted any association with CYP3A4 enzymatic activity. As an additional factor, erlotinib is also a substrate of P-glycoprotein and the ABCG2 drug transporter [21] , and respective inducers or inhibitors of the latter transporters may additionally impact the metabolism and elimination of erlotinib via alternative, non-CYP3A4 routes. Despite the lack of correlation between the clearance of midazolam as a CYP3A4 probe drug for erlotinib individual pharmacology, CYP3A4-mediated metabolism of erlotinib may become an important pathway, as illustrated by the reduced exposure to erlotinib following rifampicinmediated CYP3A4 induction [22] . Accordingly, midazolam may predict erlotinib PK and/or toxicity in patients with CYP3A4 induction. On the other hand, individual caffeine PK, which reflects CYP1A2 activity, modestly correlated with erlotinib PK and may be of value in predicting the individual metabolizer status of erlotinib. However, as shown in fig. 2A , C, the variability was large and the correlation weak, suggesting that factors additional to CYP1A2 activity influence the individual erlotinib plasma concentrations. Such factors include CYP3A4 activity as mentioned above, CYP1A1 activity that was not assessed in this trial, drug-drug and also food-drug interactions. Direct determination of the plasma or blood erlotinib concentrations may be a more suitable way to monitor and individualize therapy with erlotinib. In accordance with previous data showing CYP1A1 and CYP1A2 induction by smoking [23] , we found a correlation between current smoking status and higher CYP1A2 activity.
In accordance with what has been published previously, we found a numerical, though not statistically significant correlation between a decrease in individual erlotinib clearance and an increase in erlotinib-related rash. Tiseo and colleagues described 56 patients with stage IV NSCLC receiving erlotinib in second-or third-line treatment, and the authors found higher erlotinib serum concentrations in patients experiencing erlotinib-related grade 3 rash [24] . As only four of the 36 patients in the present study experienced erlotinib-related grade 3 rash, this may have made it more difficult to find a clear correlation between the erlotinib metabolizer status and rash. Additionally, six of the 36 patients received prophylactic minocycline that may also have obscured the correlation between erlotinib PK and skin rash.
This study additionally assessed the feasibility and validity of performing erlotinib TDM using DBS. PK sampling from DBS was shown to adequately predict individual plasma concentrations of erlotinib and could potentially be used for erlotinib TDM. Erlotinib has previously been suggested to be a candidate for TDM, as a consequence of the high interindividual PK variability that may affect efficacy and tolerability of the drug [13] . Similar to data in the literature (range of erlotinib clearance 4.85 AE 4.71 L/hr) [13, 25] , we also found a large range of erlotinib clearance (3.65 L/hr, range 1.4 to 6.8 L/hr). The best strategy to avoid clinically significant under-or overexposure of erlotinib is currently not clear, but TDM based on erlotinib plasma or blood concentrations is an option. For that, a suitable reference range has to be defined and validated by a prospective study. Besides the possibility to maximize the effectiveness of erlotinib, advantages of using direct sampling of erlotinib in patients include the possibility to detect non-compliance, drug-drug as well as food-drug interactions.
Limitations of the present study include the frequent comedication with potential PK or pharmacodynamic interactions, including PPI and minocycline, a heterogeneous study population with regard to prognosis (inclusion of patients with EGFR wild-type and EGFR-mutant NSCLC) and toxicity management (including prophylactic minocycline in a subgroup of patients), and the fact that phenotype assessment was carried out concurrently with administration of the therapeutic agent erlotinib, not completely ruling out some minor effects of drug-drug interactions. However, as erlotinib is not a relevant inducer or inhibitor of CYP [26] and no in vivo interaction has been found between erlotinib and midazolam [27] , a significant impact on the metabolism of the probe drugs used seems unlikely. The concurrent administration of the two CYP3A4 substrates erlotinib and midazolam may have resulted in saturation of CYP3A4-mediated drug elimination, although CYP3A4 usually has a substantial over-capacity, and potential CYP3A4 saturation would be expected to decrease the elimination of both erlotinib and midazolam to a comparable extent. To account for the heterogeneous study population, we used multivariate regression models accounting for known predictive and prognostic covariates. This study population proofed the feasibility and value of probe drug phenotyping and plasma/blood drug concentration monitoring in an unselected, practice-based group of patients.
In conclusion, the present data suggest that probe drug phenotyping is unlikely to substitute erlotinib TDM in patients with advanced NSCLC, but erlotinib PK sampling from DBS may replace more invasive venous sampling and facilitate TDM in cancer patients.
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